Immune regression of visceral metastases in athymic mice. Correlation of "low-level" in vitro cell-mediated cytotoxic reactions with allograft rejection in vivo

Transplantation
R H WiltroutM K Morrison

Abstract

The MDAY-D2 tumor of DBA/2 origin metastasizes widely and predictably in syngeneic DBA/2 mice, as well as in allogeneic athymic mice. BALB/c mice, which are H-2 compatible with MDAY-D2, reject the tumor based on non-H2 histocompatibility antigens. This rejection corresponds directly with the generation of a "low-level," in vitro, cell-mediated cytotoxic response in ipsilateral peripheral lymph nodes and spleen. Production of cytotoxic antibody also occurs during tumor rejection. Previous work has demonstrated the effectiveness of adoptively transferred, sensitized BALB/c lymphocytes in eliminating preexisting visceral metastases in BALB/c athymic mice. The present study shows that in this model the complete regression of H-2-compatible allografts, in the form of preexisting metastases, correlates directly with the ability of adoptively transferred cells to mediate low-level, cell-mediated cytotoxicity in vitro. Both graft rejection in vivo and cell-mediated cytotoxicity in vitro are mediated by T cells. Enriched sensitized B cells and anti-MDAY-D2 serum are both incapable of mediating this graft rejection in vivo. Based on these findings, we conclude that relatively weak in vitro cell-mediated cytotoxic responses should not be ...Continue Reading

Citations

Jan 1, 1984·Cancer Metastasis Reviews·F E Sharkey, J Fogh
May 14, 2003·Transplantation Proceedings·S M Stepkowski
Nov 26, 2008·Radiation Research·Hongyu JiangGuanjun Wang
Jan 1, 1983·Cancer Metastasis Reviews·P Frost, R S Kerbel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.